계명대학교 의학도서관 Repository

Paroxysmal and persistent atrial fibrillation ablation outcomes with the pulmonary vein ablation catheter GOLD duty-cycled phased radiofrequency ablation catheter: quality of life and 12-month efficacy results from the GOLD Atrial Fibrillation Registry

Metadata Downloads
Author(s)
Lucas BoersmaEdward KoźlukGiampiero MagliaJoão de SousaOlaf GrebeLars EckardtRobert B HokansonLauren A HemingwayEkaterina OsternHyoung-Seob ParkGiovanni RovarisFernando ArribasChristoph ScharfZoltán CsanádiÁngel ArenalFrancesco LaurenziMartijn KlaverAndreas Goette
Keimyung Author(s)
Park, Hyoung Seob
Department
Dept. of Internal Medicine (내과학)
Journal Title
Experimental and clinical transplantation
Issued Date
2020
Volume
22
Issue
6
Keyword
Atrial fibrillationCatheter ablationPhased radiofrequencyPVACElectrophysiologyPulmonaryvein isolation
Abstract
Aims:
The GOLD AF Registry has been designed to prospectively assess the population, indications, and outcomes using second-generation phased radiofrequency (RF) ablation (pulmonary vein ablation catheter GOLD) in a global examination of standard-of-care use for the treatment of paroxysmal and persistent atrial fibrillation (AF).

Methods and results:
GOLD AF (NCT02433613) is a prospective, observational, multi-centre registry designed to characterize efficacy and safety of phased RF ablation in patients with AF. The primary endpoint was freedom from AF recurrence at 12-month follow-up after a 90-day blanking period. Ancillary objectives include safety, procedural efficiency, and quality of life (QoL). The QoL assessment using the Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) and the European Heart Rhythm Association (EHRA) Score of AF-related symptoms was collected at baseline and 12 months. In total, 1054 patients were included in this analysis (age 60.6, 67.6% male, 26.5% PersAF). Kaplan-Meier estimate of freedom from AF recurrence was 77.7% at 12 months. Peri-procedural device or procedure-related complications were observed in 26 (2.5%) patients, with a low stroke rate of 0.3%. One-year post-ablation, the EHRA AF Symptom score decreased in 68% of patients. The AFEQT score improvement was observed in 88.4% and 90.4% of patients who completed the questionnaire in-person or interviewed by phone at 12 month follow-up, respectively.

Conclusion:
Phased RF ablation for the treatment of paroxysmal and persistent AF demonstrated a 77.7% freedom from AF recurrence at 12 months in addition to a significant reduction in arrhythmia symptoms and clinically meaningful improved QoL. Low peri-procedural complication rate of <3% was reported.
Keimyung Author(s)(Kor)
박형섭
Publisher
School of Medicine (의과대학)
Citation
Lucas Boersma et al. (2020). Paroxysmal and persistent atrial fibrillation ablation outcomes with the pulmonary vein ablation catheter GOLD duty-cycled phased radiofrequency ablation catheter: quality of life and 12-month efficacy results from the GOLD Atrial Fibrillation Registry. Experimental and clinical transplantation, 22(6), 888–896. doi: 10.1093/europace/euaa042
Type
Article
ISSN
1532-2092
Source
https://academic.oup.com/europace/article/22/6/888/5812743
DOI
10.1093/europace/euaa042
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/43072
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.